PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma-Reference-Cited by-同舟云学术

PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma

Published:2014-03-13 Issue:11 Volume:370 Page:1008-1018
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Gopal Ajay K.,Kahl Brad S.,de Vos Sven,Wagner-Johnston Nina D.,Schuster Stephen J.,Jurczak Wojciech J.,Flinn Ian W.,Flowers Christopher R.,Martin Peter,Viardot Andreas,Blum Kristie A.,Goy Andre H.,Davies Andrew J.,Zinzani Pier Luigi,Dreyling Martin,Johnson Dave,Miller Langdon L.,Holes Leanne,Li Daniel,Dansey Roger D.,Godfrey Wayne R.,Salles Gilles A.

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1314583

Cited by 952 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FDA-approved small molecule kinase inhibitors for cancer treatment (2001–2015): Medical indication, structural optimization, and binding mode Part I;Bioorganic & Medicinal Chemistry;2024-09

2. BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia;Expert Review of Hematology;2024-08-21

3. Mutations in Ras homolog family member A in patients with peripheral T-cell lymphoma and implications for personalized medicine;Cancer Biology & Medicine;2024-08-09

4. The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study;HemaSphere;2024-08

5. Diagnosis, management and follow‐up of follicular lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance;Internal Medicine Journal;2024-08